Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.50 |
| ▸ | ARG2 | P78540 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | BHMT | Q93088 | 2/20 | 0.44 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162122 | 1.00 | ARG1 (0.50) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL14418415 | 0.88 | NOS2 (0.50) | ARG1ARG2NOS2NOS1NOS3 | |
| Alanine SCHEMBL9937851 | 0.86 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| Alanine SCHEMBL9937848 | 0.86 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| Alanine SCHEMBL9937853 | 0.86 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36935 | 0.86 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36934 | 0.86 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL29393779 | 0.86 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL7845774 | 0.86 | GABRR1 (0.46) | GABRR1ENPEP | |
| SCHEMBL29378137 | 0.86 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282397-B1 | USE OF COMPOUNDS CONTAINING A THIO-ETHER, SULPHOXIDE OR SULPHONE FUNCTION AS COSMETIC ANTI-POLLUTION AGENT | OREAL (FR) | 2005-05-04 | — | — | EP | claimed |
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | L'OREAL (FR) | 2004-02-26 | — | — | US | claimed |
| EP-0858319-B1 | USE OF CARBOXYLIC ACIDS HAVING A SULPHUR FUNCTION FOR PROMOTING SKIN EXFOLIATION OR STIMULATING EPIDERMAL REGENERATION | OREAL (FR) | 2003-07-23 | — | — | EP | claimed |
| US-6153649-A | Use of carboxylic acids having a sulphur function for promoting skin exfoliation or stimulating epidermal regeneration | L'OREAL (FR) | 2000-11-28 | — | — | US | claimed |
| US-20260027162-A1 | MUCISPIRILLUM COMPOSITIONS AND CANCER TREATMENT METHODS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4555326-A2 | MUCISPIRILLUM COMPOSITIONS AND CANCER TREATMENT METHODS THEREOF | President And Fellows Of Harvard College (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4319746-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2024015955-A2 | MUCISPIRILLUM COMPOSITIONS AND CANCER TREATMENT METHODS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2022216848-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220142955-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | Hemoshear Therapeutics, Inc. | 2022-05-12 | — | — | US | disclosed |
| EP-3937922-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | Hemoshear Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113557014-A | Method for treating organic acidemia | 止血治疗有限公司 | 2021-10-26 | — | — | CN | disclosed |
| WO-2020186216-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | HEMOSHEAR THERAPEUTICS, LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | L'OREAL (FR) | 2004-02-26 | — | — | US | disclosed |
| US-6153649-A | Use of carboxylic acids having a sulphur function for promoting skin exfoliation or stimulating epidermal regeneration | L'OREAL (FR) | 2000-11-28 | — | — | US | disclosed |
| EP-0180672-B1 | PROCESS FOR THE PRODUCTION OF FLAVOR ENHANCING SEASONINGS | AJINOMOTO CO., INC. (JP) | 1988-09-21 | — | — | EP | disclosed |
| US-4741914-A | WITH GLUTAMIC ACID SALT | AJINOMOTO CO., INC. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0180672-A1 | Process for the production of flavor enhancing seasonings | AJINOMOTO CO., INC. (JP) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027162-A1 | MUCISPIRILLUM COMPOSITIONS AND CANCER TREATMENT METHODS THEREOF | SAAL1, CD74, MUC1 | ARG1 185/4885ARG2 1637/4885NOS2 3278/4885 |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | ARG1 1222/4885ARG2 351/4885NOS2 1594/4885 |
| US-20040037856-A1 | Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent | TST, STS, MPST | ARG1 3597/4885ARG2 2687/4885NOS2 2074/4885 |
| US-20220142955-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | OTC, OAT, PCCA | ARG1 1103/4885ARG2 310/4885NOS2 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.